Sponsors / PRAX
PRAX

Praxis Precision Medicines

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
10Trials in this database
23Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Clinical Trial of PRAX-944 in Participants With Essential TremorNCT05021978Praxis Precision MedicinesPhase 2Completed2022-03-24Actual
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential TremorNCT05021991Praxis Precision MedicinesPhase 2Completed2023-02-09Actual
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)NCT05818553Praxis Precision MedicinesPhase 2, Phase 3Active not recruiting2025-11-12Actual
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)NCT06087276Praxis Precision MedicinesPhase 3Active not recruiting2025-10-10Actual
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresNCT06908356Praxis Precision MedicinesPhase 2Recruiting2025-07Estimated
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902Praxis Precision MedicinesPhase 2, Phase 3Completed2026-05-14Actual
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471Praxis Precision MedicinesPhase 3Active not recruiting2026-12Estimated
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922Praxis Precision MedicinesPhase 3Recruiting2026-12Estimated
Clinical Trial of Vormatrigine in Adult Patients With EpilepsyNCT07287163Praxis Precision MedicinesPhase 3Enrolling by invitation2028-05-31Estimated
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004Praxis Precision MedicinesPhase 3Active not recruiting2027-01Estimated

Latest recorded trial changes

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902 · Praxis Precision Medicines

· 5 fields changed

Participant count type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit
− Previous value

count: 230; type: ESTIMATED

+ Updated value

count: 255; type: ACTUAL

Completion date type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit
− Previous value

2025-11-24

+ Updated value

2026-05-14

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Completed

Check registry source
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553 · Praxis Precision Medicines

· 5 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: To assess the effect of PRAX-562 on the frequency of countable motor seizures in pediatric participants with DEEs

+ Updated value

measure: PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs; measure: PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit
− Previous value

count: 100; type: ESTIMATED

+ Updated value

count: 77; type: ESTIMATED

Completion date type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit
− Previous value

2026-03-23

+ Updated value

2025-11-12

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

NCT06087276 · Praxis Precision Medicines

· 4 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Parallel Design: Change from Baseline (CFB) to Week 12 (Day 84) on mADL11; measure: Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal; measure: Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.

+ Updated value

measure: Parallel Design: Change from Baseline (CFB) to Week 8 (Day 56) on mADL11 score; measure: Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal; measure: Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit
− Previous value

count: 600; type: ESTIMATED

+ Updated value

count: 1000; type: ESTIMATED

Primary completion date

Recorded edit
− Previous value

2024-09

+ Updated value

2025-09

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Enrolling by invitation

Check registry source